Title: Epalrestat
CAS Registry Number: 82159-09-9
CAS Name: (5Z)-5-[(2E)-2-Methyl-3-phenyl-2-propenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid
Additional Names: 5-[(E,E)-b-methylcinnamylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid; 3-carboxymethyl-5-(2-methylcinnamylidene)rhodanine
Manufacturers' Codes: ONO-2235
Trademarks: Kinedak (Ono); Sorbistat (Ono)
Molecular Formula: C15H13NO3S2
Molecular Weight: 319.40
Percent Composition: C 56.41%, H 4.10%, N 4.39%, O 15.03%, S 20.08%
Literature References: Aldose reductase inhibitor. Prepn: T. Tadao et al., EP 47109; eidem, US 4464382 (1982, 1984 both to Ono Pharmaceutical). Inhibitory effect on aldose reductase in vitro: H. Terashima et al., J. Pharmacol. Exp. Ther. 229, 226 (1983). Effect on motor nerve conduction and sorbitol levels in diabetic rats: R. Kikkawa et al., Diabetologia 24, 290 (1983). Effect in rats on peripheral nerve dysfunction: eidem, Metabolism 33, 212 (1984); on retinal microangiopathy: K. Kojima et al., Jpn. J. Ophthalmol. 29, 99 (1985).
Properties: Crystals from ethanol-water, mp 210-217°.
Melting point: mp 210-217°
Derivative Type: N-Methyl-D-glucamine salt
Molecular Formula: C22H30N2O8S2
Molecular Weight: 514.61
Percent Composition: C 51.35%, H 5.88%, N 5.44%, O 24.87%, S 12.46%
Properties: Crystals from methanol, mp 163-165°.
Melting point: mp 163-165°
Therap-Cat: Treatment of diabetic neuropathy.
Keywords: Aldose Reductase Inhibitor.
Epanolol Eperisone Epiandrosterone Epichlorohydrin Epicholestanol

CAS number 82159-09-9 YesY
PubChem 1584822
ChemSpider 1285910 N
KEGG D01688 YesY
Jmol-3D images Image 1
Molecular formula C15H13NO3S2
Molar mass 319.401 g/mol
Density 1.43 g/mL
Melting point 210 °C; 410 °F; 483 K
Boiling point 516.8 °C; 962.2 °F; 789.9 K
 N (verify) (what is: YesY/N?)
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
Infobox references

Epalrestat is an aldose reductase inhibitor.

"Long-term treatment with epalrestat is well tolerated and can effectively delay the progression of diabetic neuropathy and ameliorate the associated symptoms of the disease, particularly in subjects with good glycemic control and limited microangiopathy." [1]